The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial.
Adolescent
Adult
Antimalarials
/ administration & dosage
Asia, Southeastern
/ epidemiology
Child
Cluster Analysis
Cross-Over Studies
Disease Eradication
/ methods
Drug Resistance, Multiple
/ drug effects
Female
Humans
Malaria, Falciparum
/ diagnosis
Male
Mass Drug Administration
/ methods
Young Adult
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
18
09
2018
accepted:
15
01
2019
entrez:
16
2
2019
pubmed:
16
2
2019
medline:
19
9
2019
Statut:
epublish
Résumé
The emergence and spread of multidrug-resistant Plasmodium falciparum in the Greater Mekong Subregion (GMS) threatens global malaria elimination efforts. Mass drug administration (MDA), the presumptive antimalarial treatment of an entire population to clear the subclinical parasite reservoir, is a strategy to accelerate malaria elimination. We report a cluster randomised trial to assess the effectiveness of dihydroartemisinin-piperaquine (DP) MDA in reducing falciparum malaria incidence and prevalence in 16 remote village populations in Myanmar, Vietnam, Cambodia, and the Lao People's Democratic Republic, where artemisinin resistance is prevalent. After establishing vector control and community-based case management and following intensive community engagement, we used restricted randomisation within village pairs to select 8 villages to receive early DP MDA and 8 villages as controls for 12 months, after which the control villages received deferred DP MDA. The MDA comprised 3 monthly rounds of 3 daily doses of DP and, except in Cambodia, a single low dose of primaquine. We conducted exhaustive cross-sectional surveys of the entire population of each village at quarterly intervals using ultrasensitive quantitative PCR to detect Plasmodium infections. The study was conducted between May 2013 and July 2017. The investigators randomised 16 villages that had a total of 8,445 residents at the start of the study. Of these 8,445 residents, 4,135 (49%) residents living in 8 villages, plus an additional 288 newcomers to the villages, were randomised to receive early MDA; 3,790 out of the 4,423 (86%) participated in at least 1 MDA round, and 2,520 out of the 4,423 (57%) participated in all 3 rounds. The primary outcome, P. falciparum prevalence by month 3 (M3), fell by 92% (from 5.1% [171/3,340] to 0.4% [12/2,828]) in early MDA villages and by 29% (from 7.2% [246/3,405] to 5.1% [155/3,057]) in control villages. Over the following 9 months, the P. falciparum prevalence increased to 3.3% (96/2,881) in early MDA villages and to 6.1% (128/2,101) in control villages (adjusted incidence rate ratio 0.41 [95% CI 0.20 to 0.84]; p = 0.015). Individual protection was proportional to the number of completed MDA rounds. Of 221 participants with subclinical P. falciparum infections who participated in MDA and could be followed up, 207 (94%) cleared their infections, including 9 of 10 with artemisinin- and piperaquine-resistant infections. The DP MDAs were well tolerated; 6 severe adverse events were detected during the follow-up period, but none was attributable to the intervention. Added to community-based basic malaria control measures, 3 monthly rounds of DP MDA reduced the incidence and prevalence of falciparum malaria over a 1-year period in areas affected by artemisinin resistance. P. falciparum infections returned during the follow-up period as the remaining infections spread and malaria was reintroduced from surrounding areas. Limitations of this study include a relatively small sample of villages, heterogeneity between villages, and mobility of villagers that may have limited the impact of the intervention. These results suggest that, if used as part of a comprehensive, well-organised, and well-resourced elimination programme, DP MDA can be a useful additional tool to accelerate malaria elimination. ClinicalTrials.gov NCT01872702.
Sections du résumé
BACKGROUND
The emergence and spread of multidrug-resistant Plasmodium falciparum in the Greater Mekong Subregion (GMS) threatens global malaria elimination efforts. Mass drug administration (MDA), the presumptive antimalarial treatment of an entire population to clear the subclinical parasite reservoir, is a strategy to accelerate malaria elimination. We report a cluster randomised trial to assess the effectiveness of dihydroartemisinin-piperaquine (DP) MDA in reducing falciparum malaria incidence and prevalence in 16 remote village populations in Myanmar, Vietnam, Cambodia, and the Lao People's Democratic Republic, where artemisinin resistance is prevalent.
METHODS AND FINDINGS
After establishing vector control and community-based case management and following intensive community engagement, we used restricted randomisation within village pairs to select 8 villages to receive early DP MDA and 8 villages as controls for 12 months, after which the control villages received deferred DP MDA. The MDA comprised 3 monthly rounds of 3 daily doses of DP and, except in Cambodia, a single low dose of primaquine. We conducted exhaustive cross-sectional surveys of the entire population of each village at quarterly intervals using ultrasensitive quantitative PCR to detect Plasmodium infections. The study was conducted between May 2013 and July 2017. The investigators randomised 16 villages that had a total of 8,445 residents at the start of the study. Of these 8,445 residents, 4,135 (49%) residents living in 8 villages, plus an additional 288 newcomers to the villages, were randomised to receive early MDA; 3,790 out of the 4,423 (86%) participated in at least 1 MDA round, and 2,520 out of the 4,423 (57%) participated in all 3 rounds. The primary outcome, P. falciparum prevalence by month 3 (M3), fell by 92% (from 5.1% [171/3,340] to 0.4% [12/2,828]) in early MDA villages and by 29% (from 7.2% [246/3,405] to 5.1% [155/3,057]) in control villages. Over the following 9 months, the P. falciparum prevalence increased to 3.3% (96/2,881) in early MDA villages and to 6.1% (128/2,101) in control villages (adjusted incidence rate ratio 0.41 [95% CI 0.20 to 0.84]; p = 0.015). Individual protection was proportional to the number of completed MDA rounds. Of 221 participants with subclinical P. falciparum infections who participated in MDA and could be followed up, 207 (94%) cleared their infections, including 9 of 10 with artemisinin- and piperaquine-resistant infections. The DP MDAs were well tolerated; 6 severe adverse events were detected during the follow-up period, but none was attributable to the intervention.
CONCLUSIONS
Added to community-based basic malaria control measures, 3 monthly rounds of DP MDA reduced the incidence and prevalence of falciparum malaria over a 1-year period in areas affected by artemisinin resistance. P. falciparum infections returned during the follow-up period as the remaining infections spread and malaria was reintroduced from surrounding areas. Limitations of this study include a relatively small sample of villages, heterogeneity between villages, and mobility of villagers that may have limited the impact of the intervention. These results suggest that, if used as part of a comprehensive, well-organised, and well-resourced elimination programme, DP MDA can be a useful additional tool to accelerate malaria elimination.
TRIAL REGISTRATION
ClinicalTrials.gov NCT01872702.
Identifiants
pubmed: 30768615
doi: 10.1371/journal.pmed.1002745
pii: PMEDICINE-D-18-03249
pmc: PMC6377128
doi:
Substances chimiques
Antimalarials
0
Banques de données
ClinicalTrials.gov
['NCT01872702']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1002745Subventions
Organisme : Wellcome Trust
ID : 101148/Z/13/Z
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist. LvS receives a stipend as a Specialty Consulting Editor for PLOS Medicine and serves on the journal's Editorial Board. NJW is a member of the Editorial Board of PLOS Medicine.
Références
BMJ. 2006 Jul 1;333(7557):18-9
pubmed: 16809709
Am J Trop Med Hyg. 1998 Feb;58(2):195-203
pubmed: 9502604
Malar J. 2014 Nov 03;13:418
pubmed: 25363455
Malar J. 2017 Nov 28;16(1):483
pubmed: 29183370
Malar J. 2017 May 19;16(1):206
pubmed: 28526019
Malar J. 2017 Jan 31;16(1):56
pubmed: 28143518
Cochrane Database Syst Rev. 2013 Dec 09;(12):CD008846
pubmed: 24318836
Am J Trop Med Hyg. 2018 Aug;99(2):350-356
pubmed: 29869601
Trends Parasitol. 2003 Oct;19(10):452-60
pubmed: 14519583
Lancet Infect Dis. 2017 Oct;17(10):1022-1023
pubmed: 28948924
Am J Trop Med Hyg. 2015 Jul;93(1):125-134
pubmed: 26013371
Lancet Infect Dis. 2016 Mar;16(3):357-65
pubmed: 26774243
Stat Med. 2018 Feb 20;37(4):572-589
pubmed: 29114926
Malar J. 2012 Oct 26;11:355
pubmed: 23101492
Malar J. 2015 Apr 24;14:165
pubmed: 25908498
N Engl J Med. 2008 Dec 11;359(24):2619-20
pubmed: 19064625
BMC Med. 2018 Oct 22;16(1):183
pubmed: 30343666
PLoS Med. 2013;10(3):e1001398
pubmed: 23472056
Wellcome Open Res. 2017 Jul 28;2:59
pubmed: 28894847
Malar J. 2015 Sep 30;14:381
pubmed: 26424000
PLoS Negl Trop Dis. 2018 Feb 14;12(2):e0006221
pubmed: 29444080
Malar J. 2016 Nov 2;15(1):523
pubmed: 27806717
J Clin Microbiol. 2014 Sep;52(9):3303-9
pubmed: 24989601
J Clin Microbiol. 2011 Aug;49(8):2946-53
pubmed: 21653767
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
J Infect Dis. 2016 Dec 15;214(12):1831-1839
pubmed: 27923947
Trans R Soc Trop Med Hyg. 1996 Mar-Apr;90(2):105-11
pubmed: 8761562
Malar J. 2018 Jun 7;17(1):226
pubmed: 29880051
Emerg Infect Dis. 2017 Apr;23(4):715-717
pubmed: 28322709
Lancet. 2016 Apr 23;387(10029):1785-8
pubmed: 26880124
Malar J. 2015 Feb 19;14:86
pubmed: 25880664
Malar J. 2016 May 27;15(1):296
pubmed: 27234446
Glob Health Action. 2017;10(1):1366136
pubmed: 28914184
Methods Mol Biol. 1996;50:263-91
pubmed: 8751365
Malar J. 2012 Mar 25;11:86
pubmed: 22443375
Malar J. 2017 Feb 14;16(1):75
pubmed: 28196536
Malar J. 2017 Oct 23;16(1):424
pubmed: 29061133
Expert Rev Anti Infect Ther. 2015 Jun;13(6):715-30
pubmed: 25831482
Clin Infect Dis. 2018 Aug 31;67(6):817-826
pubmed: 29522113
Wellcome Open Res. 2017 Feb 14;2:10
pubmed: 28612053
Clin Infect Dis. 2018 Nov 13;67(11):1670-1676
pubmed: 29846536
J Infect Dis. 2019 Apr 16;219(9):1499-1509
pubmed: 30500927
J Infect Dis. 2017 Feb 1;215(3):396-404
pubmed: 27932615
PLoS Genet. 2017 Oct 27;13(10):e1007065
pubmed: 29077712
BMJ. 2006 Jul 1;333(7557):15
pubmed: 16790458
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Malar J. 2017 Jan 13;16(1):27
pubmed: 28086775
Am J Trop Med Hyg. 2018 Jan;98(1):100-104
pubmed: 29165227
Clin Infect Dis. 2013 Mar;56(5):685-93
pubmed: 23175563
Malar J. 2012 Dec 14;11:418
pubmed: 23237606
BMC Med. 2015 Dec 22;13:305
pubmed: 26695060
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Malar J. 2017 Jan 6;16(1):17
pubmed: 28061908
Lancet. 2018 May 12;391(10133):1916-1926
pubmed: 29703425
Malar J. 2017 Sep 26;16(1):387
pubmed: 28950864
Lancet Infect Dis. 2017 May;17(5):491-497
pubmed: 28161569
J Vector Ecol. 2017 Jun;42(1):84-93
pubmed: 28504441
Malar J. 2013 Sep 17;12:329
pubmed: 24044424
PLoS One. 2012;7(10):e45797
pubmed: 23049687
Malar J. 2013 Oct 11;12:363
pubmed: 24119916
Lancet. 2000 Nov 4;356(9241):1560-4
pubmed: 11075770
Clin Infect Dis. 2018 Jul 2;67(2):295-302
pubmed: 29757358
Lancet Infect Dis. 2015 Jun;15(6):683-91
pubmed: 25877962
J Infect Dis. 2007 Apr 1;195(7):927-33
pubmed: 17330781
Jpn J Infect Dis. 2012;65(6):465-75
pubmed: 23183197
Wellcome Open Res. 2017 Sep 6;2:81
pubmed: 29062913
Antimicrob Agents Chemother. 2014 Dec;58(12):7340-6
pubmed: 25267661